Novocure Stock Price, News & Analysis

Novocure (NVCR) will present real-world data at ESMO 2024 showing improved survival outcomes for newly diagnosed glioblastoma (ndGBM) patients with increased use of Tumor Treating Fields (TTFields) therapy. The analysis suggests higher TTFields device usage is significantly associated with better survival in a broad ndGBM patient population.

The presentation, titled 'Association of Tumor Treating Fields Device Usage with Survival in Newly Diagnosed GBM: A Real-World Analysis of Patients in the US', will be displayed as Poster #459 on September 16. Novocure has also sponsored an ESMO Colloquium on the role of alternating electric fields in treating advanced non-small cell lung cancer, scheduled for September 16.

Novocure (NASDAQ: NVCR) announced significant leadership changes. CEO Asaf Danziger will retire at the end of 2024 after 22 years, succeeded by current CFO Ashley Cordova on January 1, 2025. Danziger will serve as Senior Advisor into early 2026 and remain on the Board of Directors. Additionally, COO Wilco Groenhuysen will step down on October 1, 2024, with Mukund Paravasthu, currently Senior Vice President of Product Development, transitioning to COO.

These changes mark a significant transition for Novocure, which has grown from a preclinical lab to a global company treating thousands of cancer patients with Tumor Treating Fields therapy. The company aims to expand its therapy to more indications under new leadership.

Novocure (NVCR) has announced its participation in the 2024 Wells Fargo Healthcare Conference on September 4, 2024. Executive Chairman William Doyle will engage in a fireside chat at 4:30 p.m. EST and attend one-on-one investor meetings throughout the event. A live audio webcast of the presentation will be available on Novocure's Investor Relations website and will remain accessible for at least 14 days post-event.

Investors can access Novocure's regularly updated corporate presentation on the company's Investor Relations page. Novocure utilizes this platform to disclose material non-public information and comply with Regulation FD disclosure obligations.

Novocure (NVCR) announced its participation in the 2024 World Conference on Lung Cancer, showcasing new analyses on Tumor Treating Fields (TTFields) therapy for non-small cell lung cancer (NSCLC). A post-hoc analysis of the LUNAR trial revealed no difference in overall survival benefit between patients with different BMIs, while simulation data suggested TTFields can be delivered effectively across various BMIs.

The LUNAR trial met its primary endpoint, demonstrating significant extension in overall survival for NSCLC patients treated with TTFields and standard therapies. Novocure has submitted data to regulatory agencies and anticipates treating patients in late 2024. The company will present posters and participate in symposia at the conference, focusing on TTFields' potential in lung cancer treatment.

Novocure (NVCR) reported strong Q2 2024 financial results, with net revenues of $150.4 million, up 19% year-over-year. The company had 3,963 active patients on therapy as of June 30, 2024, an 11% increase from the previous year. Key highlights include:

- Successful launch in France and improved U.S. approval rates
- Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer
- 1,634 prescriptions received, up 5% year-over-year
- Gross margin of 77%
- Net loss of $33.4 million with loss per share of $0.31
- Cash, cash equivalents, and short-term investments of $951.2 million

Novocure continues to focus on growing its commercial business in glioblastoma, launching in non-small cell lung cancer, and advancing its clinical and product development pipelines.

CereVasc, a clinical-stage medical device company, has appointed Shlomi Nachman and Timothy Scannell to its Board of Directors, effective July 11, 2024. Nachman, former Company Group Chairman at Johnson & Johnson's Medical Devices sector, brings over 25 years of industry experience. Scannell, former President and COO of Stryker , has more than 30 years of leadership experience in medical technology.

Dan Levangie, CereVasc's Chairman and CEO, expressed excitement about leveraging their expertise to bring the eShunt System to market. Both appointees have extensive backgrounds in medical devices and neurovascular fields, with Nachman's experience in cardiovascular solutions and Scannell's success in MedSurg & Neurotechnology businesses.

Novocure (NASDAQ: NVCR) will release its financial results for the second quarter of 2024 on July 25, 2024, before the U.S. markets open. A conference call and webcast are scheduled for the same day at 8:00 a.m. EDT to discuss the results. The webcast and accompanying slides will be accessible via the Investor Relations page on Novocure's website and will remain available for two weeks post-call.

Novocure (NASDAQ: NVCR) announced that the METIS Phase 3 clinical trial met its primary endpoint, significantly delaying intracranial progression in patients with brain metastases from non-small cell lung cancer (NSCLC) using Tumor Treating Fields (TTFields) therapy. The trial demonstrated a median time to intracranial progression of 21.9 months for patients treated with TTFields therapy and supportive care, compared to 11.3 months for those with supportive care alone. Quality of life deterioration-free survival was also notably prolonged in the TTFields group, with no evidence of worsening cognitive function. The data will be presented at the 2024 ASCO Annual Meeting. Key secondary endpoints did not achieve statistical significance, with median overall survival at 11.3 months for the TTFields group versus 10.6 months for supportive care alone. Novocure plans to publish these findings and submit them to regulatory authorities.

Novocure (NASDAQ: NVCR) has announced results from the TIGER study, which investigated the use of Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma (GBM) in Germany. The study, conducted from August 2017 to November 2019, included 429 patients and is the largest prospective, non-interventional study of TTFields therapy to date. Key findings indicate a median overall survival of 19.6 months and a median progression-free survival of 10.2 months. The therapy was well tolerated with no increase in systemic toxicity. One-year, two-year, three-year, and four-year survival rates were 79.2%, 42.4%, 31.5%, and 27.7%, respectively. These results align with previous phase 3 EF-14 clinical trial outcomes. The data will be presented at the 2024 American Society of Clinical Oncology Annual Meeting.